Laddar populära aktier...
Inför Q1-rapporten räknar Analysguiden med en lägre omsättning, drivet av konjunkturen och avyttring...
Redeye comments on Truecaller ahead of its Q1 results (due 7 May).
Q1e to mark low point amid organic decline... ...but we expect solid earnings development in subsequ...
Redeye returns with an update following Annexin’s Q1 report, which offered no surprises.
Q1e: Clean EBIT of ~SEK 37m Pulp prices move higher, demand stronger Fair value range: SEK 9-16/sh ...
Redeye leaves its comments following a few press releases from Acarix in the past few days.
The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the e...
Redeye comments on Modelon's news that the current CEO, Magnus Gäfvert, is set to step down from his...
We expect that cost increases will happen at a slower pace than revenue growth in 2024.
XVIVO presented the overall results from the European Heart study, based on 203 patients across 15 c...
Ascelia's confirmation yesterday that the three professional external readers has completed the imag...
Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from ...
Redeye lowers its forecasts for Q1 while leaving the rest of 2024 roughly unchanged.
Redeye provides a research update following the Q2 report published by Newbury yesterday.
Redeye notes that Neonode's CEO is leaving the company effective immediately, and therefore provides...